On the heels of the success of GLP-1s like Ozempic, other peptide treatments are flooding the marketplace—and advertising spaces. But even as the Trump administration’s FDA discusses approving more treatments and the businesses selling them proliferate, many peptides are sitting in a legal and medical gray area. So how real - and safe - is this peptide hype?

Guest: Kate Knibbs, senior writer at WIRED.

Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.

Podcast production by Rob Gunther, Evan Campbell, Madeline Thames-Ducharme and Patrick Fort.

Paige Osburn is the senior supervising producer of What Next and What Next TBD.

Hosted on Acast. See acast.com/privacy for more information.